Overview

Safety and Efficacy of PC945 in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis

Status:
Not yet recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

To assess the efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA

Phase:

Phase 3

Details

Lead Sponsor:

Pulmocide Ltd